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Abstract
Background: Airway remodeling in COPD includes reorganization of the extracellular matrix. Proteoglycans play a 
crucial role in this process as regulators of the integrity of the extracellular matrix. Altered proteoglycan 
immunostaining has been demonstrated in COPD lungs and this has been suggested to contribute to the 
pathogenesis. The major cell type responsible for production and maintenance of ECM constituents, such as 
proteoglycans, are fibroblasts. Interestingly, it has been proposed that central airways and alveolar lung parenchyma 
contain distinct fibroblast populations. This study explores the hypothesis that altered depositions of proteoglycans in 
COPD lungs, and in particular versican and perlecan, is a result of dysregulated fibroblast proteoglycan production.
Methods: Proliferation, proteoglycan production and the response to TGF-β1 were examined in vitro in centrally and 
distally derived fibroblasts isolated from COPD patients (GOLD stage IV) and from control subjects.
Results: Phenotypically different fibroblast populations were identified in central airways and in the lung parenchyma. 
Versican production was higher in distal fibroblasts from COPD patients than from control subjects (p < 0.01). In 
addition, perlecan production was lower in centrally derived fibroblasts from COPD patients than from control subjects 
(p < 0.01). TGF-β1 triggered similar increases in proteoglycan production in distally derived fibroblasts from COPD 
patients and control subjects. In contrast, centrally derived fibroblasts from COPD patients were less responsive to TGF-
β1 than those from control subjects.
Conclusions: The results show that fibroblasts from COPD patients have alterations in proteoglycan production that 
may contribute to disease development. Distally derived fibroblasts from COPD patients have enhanced production of 
versican that may have a negative influence on the elastic recoil. In addition, a lower perlecan production in centrally 
derived fibroblasts from COPD patients may indicate alterations in bronchial basement membrane integrity in severe 
COPD.
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease characterized by a reduction in respira-
t o ry  a i r fl o w  t h a t  i s  n o t  po s s i b l e  t o  n o r m a l i z e  [ 1 ] .  T h e
reduced airflow is caused by tissue remodeling, including
reorganization of the extracellular matrix (ECM). In
bronchi, epithelial dysregulation results in impaired
mucocilliary clearance, over-production of mucus, and
squamous cell metaplasia. In parallel with this, subepi-
thelial fibrosis is often observed in bronchi and bronchi-
oles. Degradation of alveolar walls (emphysema) is a
hallmark of COPD, which limits the area of air-blood
exchange and the elastic recoil [2]. Other structural
changes in COPD, such as thickening of the airway wall
and reticular basement membrane, have been implicated
as factors that contribute to reduction in airflow [3,4].
Interestingly, in terms of the turnover of ECM, oppos-
ing pathological processes occur in the COPD lung as the
ECM is degraded in alveoli and there is excessive deposi-
tion of ECM (fibrosis) in bronchi and in bronchioles [5].
The major cell type responsible for production and main-
tenance of the ECM are fibroblasts. Recently, it was sug-
gested that central airways and alveolar lung parenchyma
contain distinct fibroblast populations [6,7]. Fibroblasts
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from these anatomical sites were found to have different
morphology, proliferation, and ECM production. This
distinction is important to consider in COPD, as the
ECM turnover is different in bronchi and alveoli. A key
family of molecules for ECM integrity is the proteogly-
cans. The production of proteoglycans and other ECM
molecules ha ve been report ed t o be modula t ed by the
profibrotic signal molecule TGF-β [8,9]. Proteoglycans
have been shown to be differentially expressed in COPD
lungs [10,11]. For example, enhanced alveolar immunos-
taining of the large proteoglycan versican has been
reported in COPD patients [10]. As versican may inhibit
the assembly of elastic fibers, it may have a negative effect
on the elastic recoil and thereby possibly contribute to
the pathogenic development of COPD. Moreover, perle-
can, a heparan sulphate proteoglycan, is crucial for base-
ment membrane integrity and reduced perlecan
immunostaining has been demonstrated in the lungs of
COPD patients [11].
In this study, we hypothesized that altered levels of pro-
teoglycans in COPD lungs may be dependent on dysregu-
lated proteoglycan production in fibroblasts and hence
that there are alterations in fibroblast phenotypes in
COPD patients compared to control subjects. In particu-
lar, we wanted to determine whether enhanced alveolar
versican deposition is due to higher versican production
by distal fibroblasts. We also wanted to examine whether
perlecan production was altered in centrally derived
fibroblasts. Thus, we isolated centrally and distally
derived fibroblasts from lung explants from COPD
patients and from biopsies from healthy control subjects
in order to assess proteoglycan production, proliferative
potential, and responsiveness to TGF-β1 in vitro.
Methods
Patients
Patients (n = 8) suffering from very severe COPD (GOLD
stage IV) who were undergoing lung transplantation at
Lund University Hospital were included in the study. The
patients had quitted smoking at least 6 months before the
lung transplantation. Non-smokers (n = 12) with no clini-
cal history of asthma, (reversibility < 12% after adminis-
tration of the β2-agonist salbutamol (400 μg) and did not
respond to methacholine test doses (< 2,000 μg)), or other
l u n g  d i s e a s e s  w e r e  i n c l u d e d  a s  c o n t r o l  s u b j e c t s .  T h i s
study was approved by the Swedish Research Ethical
Committee in Lund (FEK 91/2006 and FEK 213/2005).
Isolation of cells
Fibroblasts were isolated from explants from COPD
patients and from bronchial and transbronchial biopsies
from control subjects as previously described [12].
Briefly, biopsies from control subjects were immediately
after sampling transferred to cell culture medium
(DMEM supplemented with 10% FBS, Gentamicin, PEST,
and Ampotericin B (all from Gibco BRL, Paisley, UK)).
Specimens from the lung explants were dissected directly
after removal from the COPD patients and were immedi-
ately transferred to cell culture medium. Bronchial tissue
was collected from the luminal side from the same locali-
sation as where bronchial biopsies were taken and were
chopped into small pieces. Alveolar parenchymal speci-
mens from explants were collected 2-3 cm from the
pleura in the lower lobes, i.e. from the same location as
where transbronchial biopsies were taken. Vessels and
small airways were removed from the peripheral lung tis-
sues and the remaining tissues were chopped into small
pieces. After rinsing, bronchial and parenchymal pieces
from explants and biopsies were allowed to adhere to the
plastic of cell culture flasks for 4 h and were then kept in
c e l l  c u l t u r e  m e d i u m  i n  3 7 ° C  c e l l  i n c u b a t o r s  u n t i l  o u t -
growth of fibroblasts were observed. Bronchial and
parenchymal fibroblasts were then referred to as central
and distal fibroblasts, respectively. Experiments were per-
formed at passages 3-6. The cell cultures were continu-
ously stained to verify the mesenchymal identity and to
estimate the purity. In the few cases when the cellular
staining was less clear then the cell morphology was veri-
fied to be representative for the culture as a whole.
Proliferation assay
Proliferation was determined as previously described
[13]. Briefly, cells were plated and fixed after 6, 24, 48, h.
Cells were stained with Crystal Violet and cell numbers
were quantified indirectly by absorbance at 595 nm on a
spectrophotometer plate reader (ELX800; Biotek Instru-
ments, Winooski, VT,). Proliferation was defined as
absorbance at 48 h divided by the absorbance after 6 h.
With this method the amount of adsorbed dye has been
shown to be proportional to the cell number recorded on
a Coulter counter [14].
Immunohistochemistry
Staining of fibroblasts
Fibroblasts (7000/well) grown overnight were fixed in 4%
paraformaldehyde for 15 minutes. Thereafter unspecific
binding sites were blocked by 2% BSA-TBS containing 5%
goat serum (Vector laboratories, Burlingame, CA) and
0,1% Triton X for 30 minutes. Cells were incubated with
primary antibodies: monoclonal mouse antibody against
Prolyl 4-Hydroxylase (Acris antibodies, Hiddenhausen,
Germany), monoclonal mouse IgM antibody against
Vimentin (Santa Cruz Biotechnology, Santa Cruz, CA),
monoclonal mouse IgG2a antibody against α-SMA
(Dako, Glostrup, Denmark), monoclonal IgG and anti-
body against SM22-alpha (Abcam, Cambridge, UK), and
with secondary antibodies: Alexafluor 488-conjugated
goat anti-mouse antibody and Alexafluor 555-conjugatedHallgren et al. Respiratory Research 2010, 11:55
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goat anti-mouse antibody (both from Molecular Probes
Invitrogen, Eugene, OR). The DNA-binding molecule
DAPI (Molecular Probes Invitrogen, Eugene, OR) was
used to stain cell nuclei before final mounting (Dako fluo-
rescence mounting medium, Dako, Glostrup, Denmark).
Cells were photographed using a TE2000-E fluorescence
microscope (Nikon, Tokyo, Japan) equipped with a
DXM1200C camera (Nikon, Tokyo, Japan).
Tissue staining of proteoglycans
In short, tissue, from same locations as where pieces for
cell isolations were taken, was fixed in 4% paraformalde-
hyde and embedded in paraffin. 5 μm sections were
deparaffinized, rehydrated and then pre-treated over-
night in buffer containing chondrotinase ABC (Seika-
gaku, Tokyo, Japan), in 37°C to make epitopes accessible
for antibodies. Endogenous peroxidase activity was
blocked in 3% hydrogen peroxidase (Merck, Damstadt,
Germany) followed by a 30 minutes block with 2% BSA-
TBS containing 5% serum raised in the same species as
the secondary antibodies used. Furthermore, endogenous
avidin and biotin binding sites were blocked (Vector avi-
din/biotin blocking kit, Vector laboratories, Burlingame,
CA) according to the manufacturer's protocol. Sections
were incubated with primary antibodies: rabbit poly-
clonal antibody against versican (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), mouse polyclonal antibody against
perlecan (Zymed laboratories, San Francisco, CA), goat
polyclonal antibody against biglycan (Santa Cruz Bio-
technology, Santa Cruz, CA), mouse monoclonal anti-
body against decorin (Abcam, Cambridge, UK). This was
followed by incubation with secondary antibodies: biotin-
conjugated goat anti-rabbit (Vector laboratories, Burl-
ingame, CA), biotin-conjugated horse anti-mouse (Vec-
tor laboratories, Burlingame, CA), and biotin-conjugated
donkey anti-goat (Jackson ImmunoResarch, West Grove,
PA). Sections were incubated with avidin and biotin (Vec-
tor laboratories, Burlingame, CA) according to the manu-
facturer's instructions and were developed with DAB
(Vector laboratories, Burlingame, CA) to visualize bound
antibodies and then counterstained with Mayer's hema-
toxylin. Sections were photographed using a TE2000-E
fluorescence microscope (Nikon, Tokyo, Japan) equipped
with a DXM1200C camera (Nikon, Tokyo, Japan).
Quantification of proteoglycans
Proteoglycan production in fibroblasts was determined
as previously described [15]. Briefly, cells were incubated
in sulfate-poor Dulbecco's MEM (Gibco BRL, Paisley,
UK) supplemented with 0.4% FBS w/wo 10 ng/ml TGF-
β1 (R&D Systems, Minneapolis, MN). COPD fibroblasts
had a very contractile phenotype and experiments were
therefore performed on cell culture plastics coated with
1% collagen-1 (PureCOL; Inamed Biomaterials, Fremont,
CA). This modification did not significantly alter proteo-
glycan production (data not shown). Proteoglycans were
quantified by [35S]-sulfate incorporation into glycosoam-
inoglycan side-chains measured on a scintillation counter
(Wallac; Perkin Ellmer, Boston, MA). Individual proteo-
glycans were separated by SDS-PAGE and quantified
using densitometry. The contribution of individual pro-
teoglycans to the total proteoglycan content was calcu-
lated as the value for each proteoglycan divided by the
sum of all the measured proteoglycans (versican, perle-
can, biglycan and decorin) by densitometry.
Statistics
Data are expressed as mean ± SEM. Statistical differences
between groups were determined by multiple compari-
sons using Kruskal-Wallis test. The Mann-Whitney test
was used to compare statistical differences between
groups. The Wilcoxon signed rank test was used to deter-
mine whether TGF-β1-stimulated proteoglycan produc-
tion was different from basal levels. Differences were
considered significant at p < 0.05. All analyses were per-
formed using GraphPad Prism software version 4.00
(GraphPad Software, San Diego, CA).
Results
Study subjects
Characteristics of COPD patients and control subjects
are shown in Table 1. Predicted FEV1 was 19.7% (14-24%);
(mean and range) in COPD patients. The corresponding
numbers were 106.7% (95-116%) for control subjects.
Mean age was 62 years (53-66) in the COPD group. For
control subjects the mean age was 30 years (24-41). All
the COPD patients were ex-smokers whereas none of the
controls had a history of smoking. Distal fibroblast cul-
tures were obtained from all patients and control sub-
jects, while central fibroblasts were obtained from 6 of 8
COPD patients and 7 of 12 control subjects.
Qualitative evaluation of proteoglycan localization
The localization of versican, perlecan, biglycan, and
decorin staining from one representative COPD subject
is presented in Figure 1. Immunoreactivity for perlecan
was, as expected, identified in the basement membrane of
bronchi, bronchioles and blood vessels. Unexpectedly,
the bronchial and bronchiolar reticular basement mem-
branes showed immunoreactivity for biglycan and deco-
rin. The basement membrane of pulmonary vessels were
positive for decorin but not for biglycan. The lamina pro-
pria tissue between basement membranes and smooth
muscle layers in bronchi and bronchioles was positive for
versican, biglycan, and decorin. Immunoreactivity for
these three proteoglycans was also observed in the tunica
media of pulmonary arteries, as well as in the adventia of
both bronchioles and arterioles. Staining was also present
in alveolar walls. Finally, smooth muscle cell layers cir-Hallgren et al. Respiratory Research 2010, 11:55
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cumscribing bronchi and bronchioles were slightly posi-
tive for perlecan, decorin and biglycan.
Characterization of fibroblasts
Isolated fibroblasts from COPD patients and control sub-
jects were characterized using antibodies to mesenchy-
mal markers (Figure 2). Both central and distal fibroblasts
w e r e  p o s i t i v e  f o r  α - s m o o t h  m u s c l e  a c t i n  ( α - S M A ) ,  a s
shown in Figure 2A and 2E. Furthermore, central and dis-
tal fibroblasts showed immunoreactivity for the fibroblast
markers prolyl 4-hydroxylase and vimentin (Figure 2B, C,
F and 2G). The contractile protein Sm22 has been found
to be expressed by smooth muscle cells and myofibro-
blasts but not by fibroblasts [16]. The isolated fibroblasts
were negative for sm22.
Fibroblast proliferation
The proliferative potential of isolated fibroblasts was
quantified using the crystal violet assay (Figure 3). In con-
trol subjects, central fibroblasts had a significantly lower
proliferation potential (1.72 ± 0.46) than distal fibroblasts
(2.80 ± 0.72) (p < 0.01). No such difference was observed
for fibroblasts from COPD patients. Distal fibroblasts
from COPD patients had a significantly lower prolifera-
tion potential (2.07 ± 0.27) than distal fibroblasts from
control subjects (2.80 ± 0.72) (p < 0.01). No difference
was seen between central fibroblasts from COPD patients
and control subjects.
Basal proteoglycan production
The basal proteoglycan production was investigated, as
shown in Figure 4. In control subjects, distal fibroblasts
had a significantly higher production of biglycan than
central fibroblasts (255 ± 43 vs. 81 ± 13) (p < 0.05). No
such difference was observed for fibroblasts from COPD
patients. Distal fibroblasts from COPD patients had a sig-
nificantly higher production of versican than distal fibro-
blasts from control subjects (324 ± 198 vs. 90 ± 47) (p <
0.01). Perlecan production was significantly lower in cen-
tral fibroblasts from COPD patients (111 ± 29) than in
fibroblasts from control subjects (285 ± 55) (p < 0.05).
There were no significant differences between the groups
in the basal production of decorin.
TGF-β1-induced proteoglycan production
Fibroblasts were stimulated with TGF-β1 for 24 hours and
the proteoglycan production was quantified and com-
pared to basal levels (Figure 5). In central fibroblasts from
control subjects TGF-β1 induced significant increases in
the production of versican (2.1-fold) and biglycan (3.6-
fold). In distal fibroblasts from control subjects TGF-β1
induced significant increases of versican (1.8-fold), perle-
can (1.4-fold) and biglycan (3.1-fold). However, TGF-β1
induced a significant decrease of decorin (1.4-fold) but no
change in the production of the other proteoglycans in
central fibroblasts from COPD patients. In distal fibro-
blasts from COPD patients, TGF-β1 induced significant
increases in the production of versican (2.1-fold), perle-
can (1.5-fold) and biglycan (2.9-fold). Distal fibroblasts
from COPD patients had a higher TGF-β1-response in
the production of versican (p < 0.05), perlecan (p < 0.05),
biglycan (p < 0.01), and decorin (p < 0.01) than central
fibroblasts from COPD patients. No such difference was
Table 1: COPD patients and control subjects in the study
Characteristics Controls COPD
No. 12 8
Age (range) 30 (24--41) 62 (53--66)
Pack years (range) 0 41 (25--60)
Gender, M/F in % 42/58 37/63
Lung function
FEV1 4.0 (3.0--5.4) 0.57 (0.4--0.9)
FEV1 % predicted 106.7 (95--116) 19.7 (14--24)
FVC 4.8 (3.5--6.4) 2.0 (1.3--2.8)
FEV1 % predicted/
FVC
22 (17--28) 31 (20--39)
DLCO m 1.4 (1.4--1.5)†
DLCO % predicted m 24 (14--42)§
† Only values from 4 patients. § Only values from 5 patients. m denotes that data is missing
Data is presented as mean (range)Hallgren et al. Respiratory Research 2010, 11:55
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observed between distal and central fibroblasts from con-
trol subjects.
Proteoglycan production profiles
We next examined the contribution of each proteoglycan
to the total proteoglycan production defined as the sum
of versican, perlecan, biglycan and decorin (Figure 6).
The contribution of perlecan to the total proteoglycan
production was significantly higher in distal fibroblasts
(0.19 ± 0.02) compared to central fibroblasts (0.13 ± 0.02)
from COPD patients (p < 0.05). There was no such differ-
ence in fibroblasts from control subjects. However, in
control subjects the contribution of biglycan to the total
proteoglycan production was significantly higher in distal
fibroblasts (0.26 ± 0.02) compared to central fibroblasts
(0.13 ± 0.03) (p < 0.05). There was no such difference in
fibroblasts from COPD patients. The contribution of ver-
sican to the total proteoglycan production was signifi-
cantly higher in central fibroblasts from COPD patients
(0.27 ± 0.04) than in central fibroblasts from control sub-
jects (0.12 ± 0.03) (p < 0.05). There was a similar differ-
ence (p < 0.01) between distal fibroblasts from COPD
patients (0.31 ± 0.03) and control subjects (0.15 ± 0.03) in
the contribution of versican to the total proteoglycan
production. The contribution of perlecan to the total pro-
teoglycan production was significantly lower (p < 0.01) in
central fibroblasts from COPD patients (0.13 ± 0.02) than
from control subjects (0.42 ± 0.09). A similar difference in
the contribution of perlecan was recorded between distal
Figure 1 Proteoglycan staining in lung sections from COPD pa-
tients. Representative micrographs of lung sections from one COPD 
patient. Antibodies were visualized by DAB staining (shown in brown) 
and sections were counterstained with Mayer's hematoxylin, which 
stains cell nuclei blue. A, C, E, and G (left panel) are representative mi-
crographs from the central airways (bronchi) and B, D, F, and H (right 
panel) show the small airways and parenchyma. A and B show versi-
can, C and D perlecan, E and F biglycan, and G and H decorin. L de-
notes lumen of the bronchi, and A and V denote airway and vessels, 
respectively. Black arrowheads show staining in the lamina reticularis. 
Scale bars represent 100 μm.
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Figure 2 Immunostaining of COPD fibroblasts. Isolated fibroblasts 
were immunostained to verify their mesenchymal origin. Cell nuclei 
are visualized by DAPI staining, shown in blue. A--D (upper panel): rep-
resentative micrographs of central fibroblasts. E--H (lower panel) show 
distal fibroblasts. Antibodies to α-SMA were used in A and E, antibod-
ies to prolyl 4-hydroxylase in B and F, antibodies to vimentin in C and 
G, and antibodies to sm22 in D and H. Scale bars represent 50 μm
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Figure 3 Proliferation potential of isolated fibroblasts. Prolifera-
tion potential was determined by crystal violet assay, as described in 
Methods. The data presented are those for 48 hours, as compared to 
those for 6 hours. *P < 0.01, +++P < 0.001.
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fibroblasts from COPD patients (0.19 ± 0.02) and control
subjects (0.35 ± 0.02) (p < 0.001). The contribution of big-
lycan to the total proteoglycan production was also lower
in distal fibroblasts from COPD patients (0.14 ± 0.02)
compared to from control subjects (0.26 ± 0.02) (p <
0.01). Finally, the contribution of decorin to the total pro-
teoglycan production was higher in distal fibroblasts
from COPD patients (0.36 ± 0.03) than from control sub-
jects (0.25 ± 0.03) (p < 0.05).
Discussion
Our data indicate that fibroblast in central airways are
phenotypically different from those present in the alveo-
lar parenchyma. In COPD patients the phenotypes of
these fibroblast populations are altered which may have
implications for disease development. Enhanced alveolar
versican deposition has been reported in tissue sections
from COPD patients, and this may have a negative influ-
ence on the elastic recoil. We show that this may be due
to dysregulated versican production in fibroblasts. Fur-
thermore, data indicates that there may be structural
changes linked to altered molecular composition of base-
ment membranes in cartilaginous airways in severe
COPD as the perlecan production was lower and perle-
can is important for the basement membrane integrity.
Surprisingly, central fibroblasts from COPD patients
were poor responders to the pro-fibrotic mediator TGF-
β1.
Figure 4 Basal proteoglycan production. Fibroblasts were incubated for 24 hours in cell medium containing 0.4% serum, and proteoglycan con-
tent in medium was determined by the ability to incorporate [S35]-sulphate into glycosoaminoglycan side chains. Values were related to protein con-
centration in the respective cell layers to account for variability in cell numbers. Individual proteoglycans were separated and quantified on SDS-PAGE 
gels to determine the contribution of each to the total proteoglycan content. Graph A shows production of versican, B perlecan, C biglycan, and D 
decorin. * P < 0.05, ** P < 0.01, + P < 0.05, ++ P < 0.01 and +++ P < 0.001.
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Our data support the idea that there are unique and
phenotypically different fibroblast populations in central
airways and in the lung parenchyma [6,7]. Kotaru et al.
reported morphological differences between central
fibroblasts, which were larger and had more projections,
and distal fibroblasts, which were thinner and more spin-
dle-shaped [6]. We observed similar differences in fibro-
blasts from both COPD patients and control subjects. In
addition, distal fibroblast had a higher proliferation
potential than central fibroblasts from control subjects. A
similar difference has been demonstrated in fibroblasts
from asthma patients [6]. Furthermore, in the present
study, a lower proliferation potential was observed in dis-
tal fibroblasts from COPD patients than from control
subjects. This is consistent with previous studies [17-19].
In one study, cigarette smoke was shown to reduce the
proliferation of fibroblasts [19]. As the COPD patients in
this study have been heavy smokers, with a smoking bur-
den of between 25 and 60 pack years, one could speculate
that this may contribute to the lower proliferation poten-
tial.
Our data show that the production of biglycan was
higher in distal fibroblasts than in central fibroblasts
from control subjects. This difference was not observed
Figure 5 Proteoglycan production after TGF-β1 stimulation. Fibroblasts were incubated for 24 hours in cell medium containing 0.4% serum and 
10 ng/ml TGF-β1, and proteoglycan content in medium was determined by the ability to incorporate [S35]-sulphate into glycosoaminoglycan side 
chains. Values were related to protein concentration in the respective cell layers to account for variability in cell numbers. Individual proteoglycans 
were separated and quantified on SDS-PAGE gels to determine the contribution of each to total proteoglycan content. Each point represents the fold 
change after TGF-β1 stimulation compared to basal levels. Dashed lines show the basal level of production of each proteoglycan. Graph A shows rel-
ative change of versican, B perlecan, C biglycan, and D decorin. * P < 0.05, ** P < 0.01 and + P < 0.05. # < 0.05, ## < 0.05 and ### < 0.001 indicate sig-
nificant differences in the proteoglycan production after TGF-β1 stimulation compared to basal levels for each group.
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in COPD patients. Interestingly, biglycan has previously
been reported to promote cytoskeletal changes resulting
in a more migratory phenotype which may be important
in wound healing processes [20]. Furthermore, the pro-
teoglycan production response to TGF-β1 did not differ
between central and distal fibroblasts from control sub-
jects. However, the production of all the investigated pro-
teoglycans was higher in distal fibroblasts than in central
fibroblasts from COPD patients following TGF-β1-stimu-
lation. It cannot be explained with a dysregulated
response in distal fibroblasts as it was similar in fibro-
blasts from COPD patients and control subjects. A more
plausible explanation is that central fibroblasts from
COPD patients are poor TGF-β1-responders. This is
intriguing as bronchial remodeling in COPD often
includes deposition of ECM and TGF-β1 is believed to be
one of the most prominent inducer of matrix production
in fibroblasts. Several studies have reported increased
expression of TGF-β1 in the airway epithelium and sub-
mucosa of patients with COPD and this was proposed to
be a product of cigarette smoke as control smokers had
similar staining pattern [21-23]. One could speculate that
bronchial fibroblasts from COPD patients have been
adapted to a local milieu with high concentration of TGF-
β1 and have as a consequence become less responsive. In
the present study TGF-β1 induced an increase in proteo-
glycan production in distal fibroblasts from COPD
patients. TGF-β1-induced transcription of versican, per-
lecan, and biglycan requires a functional downstream
Figure 6 Profile of proteoglycan production. Fibroblasts were incubated for 24 hours in cell medium containing 0.4% serum, and individual pro-
teoglycans were separated and quantified on SDS-PAGE gels to determine the contribution of each to the total proteoglycan production. Each point 
shows the relative contribution of individual proteoglycans to the total proteoglycan content defined as the sum of versican, perlecan, biglycan and 
decorin (set as 1). Graph A shows versican, B perlecan, C biglycan, and D decorin. * P < 0.05, ** P < 0.01, *** P < 0.001, + P < 0.05, ++ P < 0.01, +++ P < 0.001.
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SMAD signalling pathway [24,25]. This contrasts with a
recent study reporting defective repair functions, includ-
ing migration and contraction, in distal fibroblasts from
moderate and severe COPD patients compared to control
smokers [26]. The defective repair capability was partially
explained by dysregulation of the SMAD signalling path-
way. The conflicting results may be explained by differ-
ences in control groups as we have non-smokers and
Togo et al. have smokers with similar smoking history as
the COPD patients. Furthermore, it cannot be excluded
that the use of biopsy material as the source of control
fibroblasts in the present study also may contribute to the
difference.
To the best of our knowledge, this is the first study to
examine the proteoglycan production in both centrally
and distally derived fibroblasts from COPD patients. In
our study, an alteration in proteoglycan production was
observed in fibroblasts from COPD patients. Versican
production was higher in distal fibroblasts from COPD
patients than in distal fibroblasts from control subjects.
This is consistent with a study that reported increased
versican mRNA-expression in distal fibroblasts from
COPD patients (GOLD stages II and IV) compared to
smoking controls [27]. It is also supported by a recent
study showing increased immunostaining of versican in
alveolar walls and rims in COPD patients (GOLD stages I
and II) relative to control subjects [10]. The amount of
versican staining was also reported to be negatively corre-
lated to both elastic fiber volume and to FEV1. Previous
results from the same group showed that cellular modu-
lations that caused a decrease in versican content or the
chondroitin-sulfate side chain content of versican
enhanced protoelastin synthesis and elastic fiber assem-
bly in smooth muscle cells [28,29]. These results under-
score a role for versican as a negative regulator of elastin.
Structural changes in the small airway wall, including
basement membranes, have been suggested to contribute
to airflow obstruction in COPD [3]. Less is known about
the contribution of structural changes to airflow obstruc-
t i o n  i n  l a r g e r  a i r w a y s ,  a l t h o u g h  a n  i n v e r s e  c o r r e l a t i o n
between airway wall thickness and measures of airflow in
cartilaginous airways has been reported [4]. In the pres-
ent study we observed positive staining for decorin and
biglycan in the lamina reticularis, which is normally
exclusively composed of collagen I, collagen III, collagen
V, laminins, fibronectin, and tenascin. In addition, perle-
can production was significantly lower in central fibro-
blasts from COPD patients than in central fibroblasts
from control subjects. Perlecan is a large (> 400 kD)
multi-domain heparin sulfate proteoglycan, and a com-
ponent of the lamina densa in basement membranes of
airways and vessels [30]. Knockout studies have sug-
gested that perlecan may be important for basement
membrane integrity, and loss of perlecan may render
laminins more susceptible to proteolysis [31-33].
An interesting observation in the present study was the
shift in the relative production of individual proteogly-
cans. Distally derived fibroblasts from COPD patients
had higher production of versican and decorin and a
lower production of perlecan and biglycan than distal
fibroblasts from control subjects relative to the total
amount of proteoglycan production. Surprisingly, these
data are consistent with a rat model investigating bleomy-
cin-induced pulmonary fibrosis, which showed that big-
lycan production was increased early in the fibrotic
process and declined over time, while decorin production
was enhanced later in this process [34]. In a subsequent
study, it was shown that fibroblasts from patients with
pulmonary fibrosis produced relatively more decorin
compared to the total proteoglycan content than control
subjects [35]. These results indicate that the proteoglycan
production in distal fibroblasts from severe COPD is sim-
ilar to that in fibroblasts in a late fibrotic process. One
could speculate that signals in the deteriorating environ-
ment of the emphysematous lungs stimulate fibroblasts
to produce decorin and versican in an attempt restore the
tissue, but as versican has a negative effect on the elastic
recoil it leads to disease progression instead of resolution.
The present study was based on fibroblasts isolated
from lung explants from COPD patients undergoing lung
transplantation and from bronchial and transbronchial
biopsies from control subjects. As lung tissue from the
two groups is acquired from different sources it may be a
potential caveat. Transbronchial biopsies are primarily
composed of alveolar tissue but there is a risk of contami-
nation with small airway structures. It was reported that
distal lung sampling via transbronchial biopsies contains
small airways in one in four to eight biopsies [6]. We have
carefully evaluated our material and observed small air-
ways in one in twenty to twenty-five biopsies. However,
when present, the small airways component only consti-
tutes a small volume of the entire tissue sample. We are
therefore confident that the majority of the fibroblast cul-
tures originate from alveolar tissue. The two groups were
not age-matched, and it cannot be excluded that some of
the observed differences were a result of this difference.
Transbronchial biopsy sampling is an invasive and poten-
tially harmful procedure for subjects; thus, it would not
be ethically appropriate to sample older subjects. There
have been studies reporting age-dependent changes in
the composition of glycosoaminoglycan side chains of
decorin and heparan sulphate proteoglycans, such as per-
lecan, but there has been no evidence of age-related
quantitative differences in proteoglycan expression
[36,37]. The COPD patients in the present study were all
ex-smokers while the controls were non-smokers, and itHallgren et al. Respiratory Research 2010, 11:55
http://respiratory-research.com/content/11/1/55
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cannot be ruled out that some of the changes seen could
have been due to smoking.
Conclusions
In summary, the present study supports the idea of the
existence of phenotypically distinct fibroblast popula-
tions in central airways and in the lung parenchyma. In
addition, we show that fibroblasts isolated from COPD
patients have alterations in proteoglycan production that
may have implications for the pathogenesis. Distally
derived fibroblasts from COPD patients had higher versi-
can production, which may have a negative influence on
the elastic recoil. Centrally derived fibroblasts from
COPD patients had lower production of the basement
membrane-stabilizing proteoglycan perlecan, and immu-
nostaining of lung sections showed altered deposition of
biglycan and decorin in the basement lamina reticularis.
These abnormalities in airway basement membrane com-
position in COPD are likely to have functional conse-
q u e n c e s  a n d  m a y  t h u s  b e  r e g a r d e d  a s  a  p a t h o g e n i c
feature in the disease.
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